Treatment of metastatic clear-cell or papillary renal carcinoma with orellanine

A Phase I/II, Open-Label, Single-Arm Study on Safety, Tolerability and Anti-Tumour Efficacy of Orellanine Treatment in Patients With Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

This study is testing a new drug called orellanine to see if it can safely help people with advanced clear-cell or papillary kidney cancer when other treatments aren't working well.

Quick facts

• Phase: Phase1; Phase2
• Study type: Interventional
• Enrollment: 75 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Oncorena AB (Industry-sponsored)
• Drugs / interventions: radiation
• Locations: 5 sites (Palo Alto, California and 4 other locations)
• Trial ID: NCT05287945 on ClinicalTrials.gov

What this trial studies

This open-label phase I/II study evaluates the safety, tolerability, and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma. The trial will enroll up to 50 patients, starting with a dose escalation phase followed by a dose exposure phase. In the second phase, an additional 30 patients will be recruited to further assess the drug's safety and efficacy. The study aims to provide insights into a new treatment option for patients with limited conventional therapies available.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed advanced clear-cell or papillary renal carcinoma and no available conventional therapies.

Not a fit: Patients with early-stage renal cell carcinoma or those who have effective conventional treatment options may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could offer a new therapeutic option for patients with advanced renal cell carcinoma who have no other effective treatments.

How similar studies have performed: While this approach is novel, similar studies targeting advanced renal cell carcinoma have shown promise in exploring new treatment avenues.

Eligibility criteria

Inclusion criteria:

1. Has provided written informed consent.
2. Has a diagnosis of histologically confirmed advanced ccRCC or pRCC. No conventional therapy is available or considered appropriate by the treating physician or is declined by the patient.
3. For patients in the expansion portion of the study only: Measurable disease per RECIST version 1.1 criteria.
4. ECOG performance status of 0 - 2.
5. Age ≥18 years.
6. Life expectancy ≥3 months.
7. Has acceptable haematologic laboratory values defined as:

   1. Neutrophils ≥1.5 × 10\^9/L, without growth factor stimulation within 3 weeks prior to the blood test;
   2. Platelets ≥100 × 10\^9/L;
   3. Haemoglobin ≥5.6 mmol/L (\~90 g/L). Use of erythropoietin or blood transfusions are permitted.
8. Has acceptable liver laboratory values defined as:

   1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (≤5 × ULN for patients with liver metastases
   2. Total bilirubin ≤1.5 × ULN or direct bilirubin ≤ ULN for patients with total bilirubin levels \>1.5 × ULN
   3. For patients diagnosed with Gilbert's syndrome, total bilirubin ≤2 × ULN is acceptable.
9. Must be on chronic hemodialysis (on a consistent regimen for the previous three months, with allowance for intermittent treatments as required for volume overload).
10. The patient's treating nephrologist and oncologist agree that the prospect of loss of remaining renal function resulting from this treatment will not significantly change the patient's future and chronic dialysis treatment.
11. Female patients of child-bearing potential and male patients must agree to use 2 forms of highly effective contraception for the duration of study treatment and after the last dose of orellanine for at least 3 months for males and 6 months for females.
12. For females of child-bearing potential, a negative serum pregnancy test at screening.
13. Patients who are willing and able to comply with travel requirements, scheduled visits, treatment schedule, efficacy assessments, laboratory tests, and other study procedures.

Exclusion criteria:

1. Diagnosis of any other malignancy within 2 years prior to enrolment, except for adequately treated basal cell or squamous cell skin cancer, superficial melanoma, or carcinoma in situ of the breast or of the cervix, or low grade (Gleason 7 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g., surgery, radiation, or castration)
2. Radiotherapy within 2 weeks before first dose.
3. Immuno-oncology therapy (IO) given in the last six (6) months prior to enrolment
4. Other systemic anti-cancer therapy within 2 weeks before first dose.
5. Has not recovered from AEs due to prior anti-cancer medications to at least grade 1 by CTCAE version 5.0 (except for alopecia and grade 2 neuropathy).
6. Has received any other investigational product within 4 weeks before first dose.
7. Pregnant or breastfeeding women.
8. Uncontrolled medical condition including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements, or would, in the opinion of the investigator, place the patient at increased risk.
9. QTc interval at baseline of ≥470 msec.

Where this trial is running

Palo Alto, California and 4 other locations

• Stanford — Palo Alto, California, United States (Recruiting)
• Washington University in St. Louis — St Louis, Missouri, United States (Recruiting)
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
• START Lisbon - Hospital de Santa Maria Av — Lisbon, Portugal (Recruiting)
• Karolinska University Hospital — Stockholm, Sweden (Recruiting)

Study contacts

• Study coordinator: Börje Haraldsson, M.D., Ph.D.

Conditions Carcinoma, Renal Cell